The vaccine can target up to 20 predicted individual tumor neoantigens, increasing the number of antigen-specific T cells, such as induced CD4+ and CD8+ T cells targeting 58 (60%) and 15 (16%) of 97 unique neoantigens, respectively [271]. Here, CD8A is linked to neoplasm.